Liver adenoma or hepatocellular carcinoma in MODY type 3
Renal cysts, rudimentary or bicornuate uterus, vaginal aplasia, absence of the vas deferens, epidymal cysts in MODY type 5The diagnosis of MODY is confirmed by specific gene testing available through commercial laboratories. Classification
Common or well-established forms of MODY (1% of MODY or greater) - HNF1A-(MODY3), HNF4A-(MODY1) and GCK-(MODY2), HNF1B-(MODY5), ABCC8-(MODY12), KCNJ11-(MODY13), INS-(MODY10)
Rare forms of MODY (Few families described but reasonable generic evidence for causing MODY) - NEUROD1-(MODY6), IPF1/PDX1-(MODY4), CEL-(MODY8), WSF1 and RFX6
Genes reported as causal for MODY but evidence not compelling - BLK-(MODY11), PAX4-(MODY9) and KLF11-(MODY7), APPL1-(MODY14), NKX6-1

Treatment
In some forms of MODY, standard treatment is appropriate, though exceptions occur:

In MODY2, oral agents are relatively ineffective, however most patients are managed conservatively through diet and exercise. In MODY1 and MODY3, sulfonylureas are usually very effective, delaying the need for insulin treatment. Sulfonylureas are effective in the KATP channel forms of neonatal-onset diabetes. The mouse model of MODY diabetes suggested that the reduced clearance of sulfonylureas stands behind their therapeutic success in human MODY patients, but Urbanova et al. found that human MODY patients respond differently to the mouse model and that there was no consistent decrease in the clearance of sulfonylureas in randomly selected HNF1A-MODY and HNF4A-MODY patients.Chronic hyperglycemia due to any cause can eventually cause blood vessel damage and the microvascular complications of diabetes.
Treatment
Initial treatments for minor erythrasma can begin with keeping the area clean and dry and with antibacterial soaps. The next level is treated with topical fusidic acid and an antibacterial solution such as clindamycin to eradicate the bacteria. For aggressive types of erythrasma, oral antibiotics such as macrolides (erythromycin or azithromycin) can be prescribed. Below is a figure showing the different types and subtypes of therapies. There is no agreement on the best treatment for this disease. There are many limitations on these treatments such as more irritation, possible allergic reactions, and ulcerations. These treatments are suitable for most ages, but for young children it should be monitored very closely. Prognosis
Erythrasma has a good prognosis if it is discovered early and properly treated. In more severe cases, it can be an indicator for another disease such as diabetes mellitus. See also
List of cutaneous conditions
Athletes foot
Tinea pedis
Woods lamp
Type 2 diabetes mellitus

References
Further reading
eMedicine
Hamann K, Thorn P (1991). "Systemic or local treatment of erythrasma? A comparison between erythromycin tablets and Fucidin cream in general practice". Scand J Prim Health Care. 9 (1): 35–9. doi:10.3109/02813439109026579. PMID 2041927. == External links ==